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Renal dysfunction in Leishmaniasis and Chagas disease 
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ABSTRACT
Visceral leishmaniasis (VL) is an endemic parasitic disease frequently found in Northeast 
Brazil and may cause acute kidney injury (AKI) and glomerulonephritis. After appropriate 
treatment, renal function recovery may occur. We describe the rare case of a patient with VL, 
who developed severe AKI requiring dialysis and was subsequently diagnosed with Chagas 
disease coinfection. After specific treatment for VL, there was partial recovery of the renal 
function, followed by the onset of Chagas disease cardiomyopathy.
KEYWORDS: Leishmaniasis. Acute kidney injury. Glomerulonephritis. Chagas disease. 
Parasitic diseases. Cardiomyopathy.
INTRODUCTION
Visceral leishmaniasis (VL), also known as Kala-Azar, is a zoonosis caused 
by a flagellate protozoan called Leishmania donovani, a parasite that lives and 
multiplies in monocytes1. Kidney involvement in VL may result in acute kidney 
injury (AKI) and glomerulonephritis. VL-associated nephropathy is still not 
completely understood2, but it may be caused by immune-complex deposition in 
renal tissues, activation of T-cells and of adhesion molecules3. Complete recovery 
may occur after treatment4,5.
We describe the case of a patient with VL, who developed severe AKI requiring 
dialysis and was subsequently diagnosed with Chagas disease coinfection. After 
specific treatment for VL and glomerulonephritis, there was partial recovery of the 
renal function, followed by the onset of Chagas disease cardiomyopathy 5 months 
later.
CASE REPORT
A 48-year-old male farmer, born in Jaguaribe and living in Pereiro, in the State 
of Ceara, Northeast Brazil, had hematuria, enlarged abdomen and skin pallor. After 
5 months, he evolved with disorientation and dyspnea on exertion and was taken 
to the hospital. Physical examination showed skin and mucous membrane pallor, 
hepatosplenomegaly and lower-limb edema.
The patient had a history of cigarettes and alcohol consumption. The first 
laboratory tests showed creatinine 4.3 mg/dL, urea 246 mg/dL (Table 1), 
hypergammaglobulinemia in plasma protein electrophoresis, in urinalysis 369 red 
cells per high-power field and proteinuria (1+/4+). Due to evident signs of AKI, 
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classified as KDIGO 3, hemodialysis was started. On the 
same day, rK39 antigen test was positiveand a bone marrow 
aspirate evidenced amastigote-like forms of Leishmania 
donovani, confirming VL diagnosis. Leishmania antigen 
dosage was not performed. Serologies for hepatitis virus 
B, C and HIV were negative. Complement test levels 
were C3-55 mg/dL and C4- 15 mg/dL. VDRL, p-ANCA, 
c-ANCA, FAN and anti-ds-DNA tests showed negative 
results. Renal biopsy showed rapidly progressive, 
post-infectious glomerulonephritis with mesangial 
hypercellularity and endocapillary proliferation (Figure 
1). Immunofluorescence was positive for IgM, C3 and 
C1q. The Polymerase Chain Reaction (PCR) assay for 
Leishmania on the renal biopsy was not performed. 
Treatment consisted of liposomal amphotericin B 200 
mg a day for 7 days and 1 g of methylprednisolone a day 
for three days. Renal function improved and dialysis was 
discontinued (Table 1). The transthoracic echocardiography 
showed ejection fraction (EF) of 51%, significant tricuspid 
regurgitation and moderate mitral regurgitation, mild 
pericardial effusion in the left ventricle (LV) and significant 
pericardial effusion in the left atrium, with eccentric LV 
hypertrophy. The patient was discharged with the following 
prescriptions: enalapril, amlodipine and prednisone 60 
mg/day. Five months later, the man sought medical care 
at the emergency room due to symptoms of cardiac 
decompensation, wheezing, irregular heart rhythm with a 
fourth heart sound. The electrocardiography showed atrial 
fibrillation and the transthoracic echocardiography showed 
EF of 25%, moderate mitral regurgitation, atrial fibrillation 
(AF) and dilated cardiomyopathy showing systolic function 
worsening. He also had positive IgG antibodies for Chagas 
disease by two methods (ELISA – titer > 1.8 and IFA – 
titer > 1:160), but there was no need for dialysis during 
this second hospitalization and the heart condition was 
defined as a complication of chronic Chagas disease. After 
compensating for his medical condition, the patient was 
discharged, is currently receiving outpatient care, and is no 
longer taking prednisone (the patient has already weaned it). 
He is currently receiving enalapril, 5 mg a day, carvedilol 
12.5 mg twice a day, digoxin 0.25 mg a day, spironolactone 
25 mg, furosemide 40 mg/day and warfarin 7.5 mg/day.
Clinical and laboratory findings, after the patient was 
discharged from the hospital, confirmed the patient’s renal 
function improvement throughout the months (Table 2).
DISCUSSION
We have described an unusual case of kidney disease 
associated with VL: rapidly progressive glomerulonephritis 
and AKI. Most commonly, kidney disease associated with 
VL shows a mild presentation, manifesting as mild to 
moderate creatinine increase and proteinuria. Mesangial 
and membranoproliferative glomerulonephritis are the 
most frequent types of glomerular diseases caused by VL5,6.
VL is an endemic disease in our region, caused by 
a flagellate protozoan called Leishmania donovani. The 
parasite lives and multiplies in monocytes. Most patients 
do not show any symptoms and may heal spontaneously1.








Hosp Stays D1 D2 D3 D5 D6 D8 D16 D18 D20 D39
HB (g/dL) 6.6 7.3 6.2 8 7.8 7.4 6.6 8.3 8.2 9.9
Leukocytes (mm³) 5,400 5,803 3,625 4,878 5,659 5,106 3143 3662 5481 5812
Platelets (mm³) 135,000 154,300 139,700 136,100 133,300 104,900 127,800 101,200 98,690
Creatinine (mg/dL) 4.3 4.2 3.9 3.1 3 2.8 2.5 2.2 2.2 2.2
Urea (mg/dL) 246 183 129 131 103 107 116 86 68
PT 1.4 1.45 1.39 1.38 1.32 1.38 1.37 1.39 1.37
APTT 1.83 1.61 1.63 1.7 1.48 1.58 1.67 2.89 1.49
Prot 24 h (mg/day) 2.35 g/24 h 51.9 mg/24 h
Figure 1 - Mesangial cell proliferation (PAS, 400 x).
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Usual symptoms are fever, chills, sweating, asthenia, 
skin and mucous membranes pallor, generalized 
microadenopathy, weight loss and hepatosplenomegaly1,3,5. 
Laboratory tests show pancytopenia, hyperglobulinemia 
and hypoalbuminemia4. Tubular and glomerular renal 
functions might be affected and the patient may develop 
proteinuria and hematuria6,7. The urinary alterations found 
in a previous report describing 11 patients were proteinuria 
in 10 (90.9%), leukocyturia in 6 (54.5%) and hematuria in 
7 patients (63.6%)6.
AKI may be attributed to dehydration, hypotension 
(pre-renal AKI) and immune-mediated glomerular 
disease (intrinsic renal AKI)8. Kidney biopsies might 
show glomerular mesangial cell proliferation or focal 
endocapillary proliferation. IgG, IgM and C3 can be observed 
in proliferation areas through immunofluorescence.5 Renal 
function can recover after specific treatment4,5.
Although the patient improved the renal function after 
receiving specific treatment for kala-azar associated with 
pulse therapy, it is possible that he was already infected 
with Trypanosoma cruzi in the first hospitalization (period 
in which the diagnosis of VL was made and hemodialysis 
was required). According to Martinez-Perez et al.9 
reactivation of preexisting chronic Chagas disease can 
occur due to immunosuppressive drugs. This manuscript 
reported worsening of renal and cardiac function, but 
the conservative treatment of prior renal disease was 
maintained. The diagnosis of Chagas disease was made 
through serological tests in the second hospitalization, 
and was defined as chronic Chagas cardiomyopathy due to 
the presence of severe heart failure associated with atrial 
fibrillation in the presence of specific IgG antibodies10. 
Parasitological tests are not routinely performed in the 
chronic phase of Chagas disease due to low parasitemia 
thus, serological tests that detect antibodies against the 
etiological agent are used11. Antitrypanosomal therapy is not 
warranted for patients with advanced Chagas heart disease, 
as the available drugs are not effective for eradication 
of preexisting pathological injuries. In these patients, 
management is focused on supportive care for heart failure, 
arrhythmia and thromboembolism12. There is evidence of 
functional and structural renal alterations after T. cruzi 
infection, whether associated with decreased renal blood 
flow or damage to the proximal tubule cells, in addition 
to significant renal interstitial inflammatory infiltrate11. 
Oliveira et al.13, in 2009, demonstrated the presence of 
severe renal lesions characterized by early glomerular 
deposition of IgM, with intense inflammatory renal 
response promoting the formation of immune complexes 
resulting in glomerulopathy with impaired renal function. 
There may be decreased renal function, especially when 
infection with high parasite load is present. The occurrence 
of glomerulonephritis in the chronic phase of the disease 
has been reported in infections by T. cruzi, as well as other 
trypanosome species, such as the African type.
Despite the occurrence of glomerulopathy associated 
with Chagas disease, the cardiac component was more 
relevant because, after heart function compensation, 
plasma creatinine and urea levels returned to the levels seen 
before the worsening of renal function during the second 
hospitalization.
CONCLUSION
This case shows the importance of including post-
infectious glomerulopathies in the differential diagnosis 
Table 2 - Exams performed during outpatient care
Post-treatment 
after discharge 3mo 
6mo - Second 
hospitalization 7mo 8mo 3y 1 y and 3 mo
HB (g/dL) 13.9 13 14.2 12.6 14 12.4
Leukocytes (mm³) 10,190 8,212 11,150 9,900 6,870 5,940
Platelets (mm³) 167,100 110,900 161,900 152,000 162,000 148,000
Creatinine (mg/dL) 1.5 1.8 1.3 1.33 1.6 1.52
Urea (mg/dL) 70 155 94 59 60 66
C3 117 (80-180)
C4 26.8 (10-40)
Albumin(g/dL) 4.0 3.7 3.8
Proteinuria 24h 2.4g v=1.6 L 945 mg/24 h 702 mg/24 h
Urine +++ protein 
20 Red blood 
cells
++ protein 
8 Red blood 
cells
+ protein 
0 Red blood 
cells
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of rapidly progressive glomerulonephritis, since recovery 
associated with renal function improvement may make 
renal replacement therapy unnecessary, with consequent 
reduction of morbidity and hospital stay. The side effects 
of immunosuppressive therapy should be better evaluated 
during the treatment of glomerulopathies in patients 
at high risk of infectious endemic diseases. Endemic 
diseases in our country, such as visceral leishmaniasis and 
Chagas disease should be investigated in cases of AKI and 
glomerulonephritis.
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